Once‐Daily Combination Therapy with Emtricitabine, Didanosine, and Efavirenz in Human Immunodeficiency Virus–Infected Patients
Open Access
- 1 August 2000
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 182 (2) , 599-602
Abstract
The safety and efficacy of a once-daily regimen that combines emtricitabine, didanosine, and efavirenz was studied among 40 previously untreated humaKeywords
This publication has 9 references indexed in Scilit:
- Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in AdultsNew England Journal of Medicine, 1999
- Virological and immunological responses to once-daily dosing of didanosine in combination with stavudineAIDS, 1999
- Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort studyThe Lancet, 1999
- The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic responseAIDS, 1999
- Comparison of the plasma pharmacokinetics and renal clearance of didanosine during once and twice daily dosing in HIV-1 infected individualsAIDS, 1998
- The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadirAIDS, 1998
- Improved Survival Among HIV-Infected Individuals Following Initiation of Antiretroviral TherapyJAMA, 1998
- A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or LessNew England Journal of Medicine, 1997
- Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosineAntimicrobial Agents and Chemotherapy, 1992